Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181895 · ClinicalTrials.gov registry record · Phase 3
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT01181895 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 348 participants.
The verdict
NCT01181895, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.
Interventions
- DRUG Placebo Inhalation Powder NDPI
- DRUG Vilanterol
- DRUG Salmeterol Inhalation Powder
- DRUG Placebo Inhalation Powder Diskus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2010-09-01 |
| Est. Completion | 2011-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01181895
The ClinicalTrials.gov registry entry for NCT01181895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Inhalation Powder NDPI is the first listed.
NCT01181895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01181895 about?
NCT01181895 is a clinical study titled "Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma". The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.
What is the current status of trial NCT01181895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2010-09-01. Estimated completion is 2011-08-26.
What interventions are being tested in trial NCT01181895?
The interventions under investigation include: Placebo Inhalation Powder NDPI (DRUG), Vilanterol (DRUG), Salmeterol Inhalation Powder (DRUG), Placebo Inhalation Powder Diskus (DRUG).
Who is sponsoring clinical trial NCT01181895?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.